Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by Fudan University.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Fudan University
Information provided by:
Fudan University
ClinicalTrials.gov Identifier:
NCT00874406
First received: April 1, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate whether preoperative TAC is able to improve progression free survival and overall survival in patients receiving liver metastasis resection of colorectal cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Colorectal Cancer |
Drug: tac + folfox4 Drug: folfox4 |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer |
Resource links provided by NLM:
Drug Information available for:
Triamcinolone diacetate
Triamcinolone acetonide
Triamcinolone
Triamcinolone hexacetonide
U.S. FDA Resources
Further study details as provided by Fudan University:
Primary Outcome Measures:
- progression free survival [ Time Frame: 5 years after operation ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- overall survival [ Time Frame: 5 years after operation ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2008 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
|
Drug: tac + folfox4
tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later: operation within 28 days after operation: folfox4
|
|
Active Comparator: 2
Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
|
Drug: folfox4
folfox4 will be done within 28 days after liver resection
|
Detailed Description:
We administered TAC(oxaliplatin,FUDR and MMC) 7 days before liver metastasis resection of colorectal cancer. The study endpoints were progression free survival and overall survival as evaluated by intent-to-treat analysis.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- age <= 75 years
- resectable liver metastasis
- remnant liver volume >= 70%
- without other organ metastasis or peritoneum metastasis
- without contradiction of cardiac and pulmonary diseases
Exclusion Criteria:
- age > 75 years
- unresectable liver metastasis
- remnant liver volume < 50%
- with other organ metastasis or peritoneum metastasis
- with contradiction of cardiac and pulmonary diseases
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00874406
Contacts
| Contact: jianmin xu, MD, PHD | 008613501984869 | xujmin@yahoo.com.cn |
Locations
| China, Shanghai | |
| Zhongshan Hospital, Fudan University | Recruiting |
| Shanghai, Shanghai, China, 200032 | |
| Contact: jianmin xu, MD, PHD 008613501984869 xujmin@yahoo.com.cn | |
| Principal Investigator: jianmin xu, MD, PHD | |
Sponsors and Collaborators
Fudan University
Investigators
| Principal Investigator: | jianmin xu, MD, PHD | department of general surgery, zhongshan hospital, fudan university |
More Information
No publications provided
| Responsible Party: | Xujianmin, Zhongshan hospital, Fudan University |
| ClinicalTrials.gov Identifier: | NCT00874406 History of Changes |
| Other Study ID Numbers: | 2009-04 |
| Study First Received: | April 1, 2009 |
| Last Updated: | April 1, 2009 |
| Health Authority: | China: Ministry of Health |
Keywords provided by Fudan University:
|
colorectal cancer liver metastasis neoadjuvant chemotherapy |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Neoplasm Metastasis Liver Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Neoplastic Processes Pathologic Processes Liver Diseases |
ClinicalTrials.gov processed this record on May 16, 2013